Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN

Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 208,035 shares of the life sciences company’s stock after buying an additional 40,166 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of Illumina worth $19,757,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. WCM Investment Management LLC lifted its position in Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after acquiring an additional 247,460 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Illumina by 1.9% in the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares during the period. AQR Capital Management LLC lifted its position in shares of Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC boosted its stake in Illumina by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after purchasing an additional 21,342 shares during the period. Finally, Bank of America Corp DE boosted its stake in Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the topic of several recent analyst reports. Robert W. Baird set a $109.00 price target on Illumina in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. JPMorgan Chase & Co. increased their price target on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Stifel Nicolaus raised their price target on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $124.47.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 2.60% of the company’s stock.

Illumina Stock Up 1.0%

ILMN opened at $153.95 on Friday. The company has a market capitalization of $23.52 billion, a P/E ratio of 34.52, a P/E/G ratio of 2.54 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm’s fifty day moving average price is $134.61 and its two-hundred day moving average price is $112.77. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business’s revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.